Astellas Pharma Return on Equity

Astellas Pharma (ALPMY) currently reports a ROE of 20.36%. That is above the Healthcare sector average of 13.26%. Use the charts on this page to explore Astellas Pharma's ROE history and peer comparisons.

Astellas Pharma's ROE of 20.36% is higher than the Healthcare sector average of 13.26%. That is roughly 53.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Astellas Pharma's current 20.36% should be judged against Healthcare norms (sector average: 13.26%) and against ALPMY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 20.36%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Astellas Pharma, and consider following ALPMY for alerts when major investors trade the stock.

Astellas Pharma is classified in the Healthcare sector. On ROE, it currently shows 20.36% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALPMY with unrelated industries.